These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Search MEDLINE/PubMed

  • Title: [Antihormonal therapy in breast cancer and mTOR inhibitors].
    Author: Heudel PÉ, Tredan O, Ray-Coquard I, Treilleux I, Guastalla JP, Bachelot T.
    Journal: Bull Cancer; 2011 Dec; 98(12):1431-7. PubMed ID: 22133994.
    Abstract:
    Hormonal dependence of breast cancer has been known for a long time, yet about half of breast cancers with estrogen receptor will not respond to antihormonal therapy. Now, we know that this resistance may be related to a dysfunction of the estrogen pathway, or that of growth factors and particularly the pathway of cell activation PI3K/Akt/mTOR. Prevention of these different mechanisms of resistance could involve combination therapies such as anti-estrogens (SERMs, aromatase inhibitors) with inhibitors of the activity of growth factors that are particularly temsirolimus and everolimus for the activation pathway cell PI3K/Akt/mTOR.
    [Abstract] [Full Text] [Related] [New Search]